NervGen Pharma (TSE:NGEN) has released an update. NervGen Pharma is nearing the completion of enrollment for its Phase 1b/2a clinical trial of ...

NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, reported its financial and operational results for the third ...

Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a ...

NervGen Pharma (TSE:NGEN) has released an update. NervGen Pharma, a clinical-stage biotech company, is set to present at the Stifel 2024 ...

Target enrollment in the chronic cohort close to completionVancouver, British Columbia--(Newsfile Corp. - September 30, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

DelveInsight's multiple sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative ...

As of 08:04 CET. Market open. Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to ...

Featured here, the Balance Sheet for NervGen Pharma Corp, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 10 period ...